The balance of Polo-like kinase 1 in tumorigenesis

Cell Division

Volumn 4, Issue , 2009, Pages

  Lu, Lin Yu ^a   Yu, Xiaochun ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 60949096831     PISSN: None     EISSN: 17471028     Source Type: Journal    
DOI: 10.1186/1747-1028-4-4     Document Type: Review

References (96)

1. Fenton B Glover DM: A conserved mitotic kinase active at late anaphase-telophase in syncytial Drosophila embryos. Nature 1993, 363(6430):637-640. 8510757
2. Weerdt van deABC Medema RH: Polo-like kinases: a team in control of the division. Cell Cycle 2006, 5(8):853-864. 16627997
3. Petronczki M Lenart P Peters JM: Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. Dev Cell 2008, 14(5):646-659. 18477449
4. Golsteyn RM Mundt KE Fry AM Nigg EA: Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol 1995, 129(6):1617-1628. 2291169 7790358
5. Arnaud L Pines J Nigg EA: GFP tagging reveals human Polo-like kinase 1 at the kinetochore/centromere region of mitotic chromosomes. Chromosoma 1998, 107(6-7):424-429. 9914374
6. Wianny F Tavares A Evans MJ Glover DM Zernicka-Goetz M: Mouse polo-like kinase 1 associates with the acentriolar spindle poles, meiotic chromosomes and spindle midzone during oocyte maturation. Chromosoma 1998, 107(6-7):430-439. 9914375
7. Hamanaka R Smith MR O'Connor PM Maloid S Mihalic K Spivak JL Longo DL Ferris DK: Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J Biol Chem 1995, 270(36):21086-21091. 7673138
8. Kumagai A Dunphy WG: Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science (New York, NY) 1996, 273(5280):1377-1380. 8703070
9. Toyoshima-Morimoto F Taniguchi E Nishida E: Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 2002, 3(4):341-348. 1084057 11897663
10. Elia AE Rellos P Haire LF Chao JW Ivins FJ Hoepker K Mohammad D Cantley LC Smerdon SJ Yaffe MB: The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 2003, 115(1):83-95. 14532005
11. Lane HA Nigg EA: Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996, 135(6 Pt 2):1701-1713. 2133970 8991084
12. Casenghi M Meraldi P Weinhart U Duncan PI Korner R Nigg EA: Polo-like kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation. Developmental cell 2003, 5(1):113-125. 12852856
13. Oshimori N Ohsugi M Yamamoto T: The Plk1 target Kizuna stabilizes mitotic centrosomes to ensure spindle bipolarity. Nature cell biology 2006, 8(10):1095-1101. 16980960
14. do Carmo Avides M Tavares A Glover DM: Polo kinase and Asp are needed to promote the mitotic organizing activity of centrosomes. Nature cell biology 2001, 3(4):421-424. 11283617
15. Elowe S Hummer S Uldschmid A Li X Nigg EA: Tension-sensitive Plk1 phosphorylation on BubR1 regulates the stability of kinetochore microtubule interactions. Genes & development 2007, 21(17):2205-2219. 1950859 17785528
16. Goto H Kiyono T Tomono Y Kawajiri A Urano T Furukawa K Nigg EA Inagaki M: Complex formation of Plk1 and INCENP required for metaphase-anaphase transition. Nature cell biology 2006, 8(2):180-187. 16378098
17. Qi W Tang Z Yu H: Phosphorylation- and polo-box-dependent binding of Plk1 to Bub1 is required for the kinetochore localization of Plk1. Molecular biology of the cell 2006, 17(8):3705-3716. 1525235 16760428
18. Mundt KE Golsteyn RM Lane HA Nigg EA On the regulation and function of human polo-like kinase 1 (PLK1): Effects of overexpression on cell cycle progression. Biochem Biophys Res Commun 1997, 239(2):377-385. 9344838
19. Carmena M Riparbelli MG Minestrini G Tavares AM Adams R Callaini G Glover DM: Drosophila polo kinase is required for cytokinesis. J Cell Biol 1998, 143(30):659-671. 2148135 9813088
20. Lu LY Wood JL Minter-Dykhouse K Ye L Saunders TL Yu X Chen J: Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Mol Cell Biol 2008, 28(22):6870-6876. 18794363
21. Musacchio A Salmon ED: The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007, 8(5):379-393. 17426725
22. Sullivan M Morgan DO: Finishing mitosis, one step at a time. Nat Rev Mol Cell Biol 2007, 8(11):894-903. 17912263
23. Ferrari S: Protein kinases controlling the onset of mitosis. Cell Mol Life Sci 2006, 63(7-8):781-795. 16465440
24. Weaver BA Cleveland DW: Does aneuploidy cause cancer?. Curr Opin Cell Biol 2006, 18(6):658-667. 17046232
25. Kops GJ Weaver BAACleveland DW: On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005, 5(10):773-785. 16195750
26. Malumbres M Barbacid M: Cell cycle kinases in cancer. Curr Opin Genet Dev 2007, 17(1):60-65. 17208431
27. Lingle WL Barrett SL Negron VC D'Assoro AB Boeneman K Liu W Whitehead CM Reynolds C Salisbury JL: Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 2002, 99(4):1978-1983. 122305 11830638
28. Pihan GA Wallace J Zhou Y Doxsey SJ: Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res 2003, 63(6):1398-1404. 12649205
29. Doxsey S Zimmerman W Mikule K: Centrosome control of the cell cycle. Trends Cell Biol 2005, 15(6):303-311. 15953548
30. Wolf G Elez R Doermer A Holtrich U Ackermann H Stutte HJ Altmannsberger HM Rubsamen-Waigmann H Strebhardt K: Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997, 14(5):543-549. 9053852
31. Knecht R Elez R Oechler M Solbach C von Ilberg C Strebhardt K: Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999, 59(12):2794-2797. 10383133
32. Tokumitsu Y Mori M Tanaka S Akazawa K Nakano S Niho Y: Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 1999, 15(4):687-692. 10493949
33. Feng YB Lin DC Shi ZZ Wang XC Shen XM Zhang Y Du XL Luo ML Xu X Han YL: Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer 2009, 124(3):578-588. 19004025
34. Jang YJ Kim YS Kim WH: Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas. Int J Oncol 2006, 29(3):589-594. 16865274
35. Kanaji S Saito H Tsujitani S Matsumoto S Tatebe S Kondo A Ozaki M Ito H Ikeguchi M: Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2006, 70(2):126-133. 16645325
36. Strebhardt K Kneisel L Linhart C Bernd A Kaufmann R: Prognostic value of pololike kinase expression in melanomas. Jama 2000, 283(4):479-480. 10659871
37. Kneisel L Strebhardt K Bernd A Wolter M Binder A Kaufmann R: Expression of polo-like kinase (PLK1) in thin melanomas: A novel marker of metastatic disease. J Cutan Pathol 2002, 29(6):354-358. 12135466
38. Wolf G Hildenbrand R Schwar C Grobholz R Kaufmann M Stutte HJ Strebhardt K Bleyl U: PAlo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 2000, 196(11):753-759. 11186170
39. Weichert W Denkert C Schmidt M Gekeler V Wolf G Kobel M Dietel M Hauptmann S: Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004, 90(4):815-821. 14970859
40. Takai N Miyazaki T Fujisawa K Nasu K Hamanaka R Miyakawa I: Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett 2001, 169(1):41-49. 11410324
41. Takahashi T Sano B Nagata T Kato H Sugiyama Y Kunieda K Kimura M Okano Y Saji S: Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003, 94(2):148-152. 12708489
42. Weichert W Kristiansen G Schmidt M Gekeler V Noske A Niesporek S Dietel M Denkert C: Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol 2005, 11(36):5644-5650. 16237758
43. Dietzmann K Kirches E von B Jachau K Mawrin C: Increased human polo-like kinase-1 expression in gliomas. J Neurooncol 2001, 53(1):1-11. 11678424
44. Ito Y Miyoshi E Sasaki N Kakudo K Yoshida H Tomoda C Uruno T Takamura Y Miya A Kobayashi K: Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer 2004, 90(2):414-418. 14735186
45. Gray PJ Jr Bearss DJ Han H Nagle R Tsao MS Dean N Von Hoff DD: Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 2004, 3(5):641-646. 15141022
46. Weichert W Schmidt M Jacob J Gekeler V Langrehr J Neuhaus P Bahra M Denkert C Dietel M Kristiansen G: Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology 2005, 5(2-3):259-265. 15855824
47. Weichert W Schmidt M Gekeler V Denkert C Stephan C Jung K Loening S Dietel M Kristiansen G: Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004, 60(3):240-245. 15176053
48. Yamada S Ohira M Horie H Ando K Takayasu H Suzuki Y Sugano S Hirata T Goto T Matsunaga T: Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 2004, 23(35):5901-5911. 15221005
49. Mito K Kashima K Kikuchi H Daa T Nakayama I Yokoyama S: Expression of Polo-Like Kinase (PLK1) in non-Hodgkin's lymphomas. Leuk Lymphoma 2005, 46(2):225-231. 15621805
50. Liu L Zhang M Zou P: Expression of PLK1 and survivin in diffuse large B-cell lymphoma. Leuk Lymphoma 2007, 48(11):2179-2183. 17943598
51. Yamamoto Y Matsuyama H Kawauchi S Matsumoto H Nagao K Ohmi C Sakano S Furuya T Oga A Naito K: Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 2006, 70(3):231-237. 16837776
52. Salvatore G Nappi TC Salerno P Jiang Y Garbi C Ugolini C Miccoli P Basolo F Castellone MD Cirafici AM: A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 2007, 67(21):10148-10158. 17981789
53. Hamanaka R Maloid S Smith MR O'Connell CD Longo DL Ferris DK: Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ 1994, 5(3):249-257. 8018557
54. Holtrich U Wolf G Brauninger A Karn T Bohme B Rubsamen-Waigmann H Strebhardt K: Induction and down-regulation of PLK, a human serine/ threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 1994, 91(5):1736-1740. 43238 8127874
55. Golsteyn RM Schultz SJ Bartek J Ziemiecki A Ried T Nigg EA: Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 1994, 107(Pt 6):1509-1517. 7962193
56. Smith MR Wilson ML Hamanaka R Chase D Kung H Longo DL Ferris DK: Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997, 234(2):397-405. 9177283
57. Spankuch-Schmitt B Bereiter-Hahn J Kaufmann M Strebhardt K: Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002, 94(24):1863-1877. 12488480
58. Liu X Erikson RL: Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003, 100(10):5789-5794. 156279 12732729
59. Spankuch-Schmitt B Wolf G Solbach C Loibl S Knecht R Stegmuller M von Minckwitz G Kaufmann M Strebhardt K: Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002, 21(20):3162-3171. 12082631
60. Nogawa M Yuasa T Kimura S Tanaka M Kuroda J Sato K Yokota A Segawa H Toda Y Kageyama S: Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 2005, 115)(4):978-985. 1062892 15761500
61. Spankuch B Matthess Y Knecht R Zimmer B Kaufmann M Strebhardt K: Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004, 96(11):862-872. 15173270
62. Zhang C Pei J Kumar D Sakabe I Boudreau HE Gokhale PC Kasid UN: Antisense oligonucleotides: Target validation and development of systemically delivered therapeutic nanoparticles. Methods Mol Biol 2007, 361:163-185. 17172711
63. Jason TL Koropatnick J Berg RW: Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 2004, 201(1):66-83. 15519609
64. Spankuch B Steinhauser I Wartlick H Kurunci-Csacsko E Strebhardt KI Langer K: Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia 2008, 10(3):223-234. 2259452 18320067
65. Stevenson CS Capper EA Roshak AK Marquez B Eichman C Jackson JR Mattern M Gerwick WH Jacobs RS Marshall LA: The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J Pharmacol Exp Ther 2002, 303(2):858-866. 12388673
66. Steegmaier M Hoffmann M Baum A Lenart P Petronczki M Krssak M Gurtler U Garin-Chesa P Lieb S Quant J: BI a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007, 17(4):316-322. 17291758
67. Lenart P Petronczki M Steegmaier M Di Fiore B Lipp JJ Hoffmann M Rettig WJ Kraut N Peters JM: The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007, 17(4):304-315. 17291761
68. Mross K Frost A Steinbild S Hedbom S Rentschler J Kaiser R Rouyrre N Trommeshauser D Hoesl CE Munzert G: Phase I dose escalation and pharmacokinetic study of BI a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2536, 26(34):5511-5517. 18955456
69. Lansing TJ McConnell RT Duckett DR Spehar GM Knick VB Hassler DF Noro N Furuta M Emmitte KA Gilmer TM: In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther 2007, 6(2):450-459. 17267659
70. Peters U Cherian J Kim JH Kwok BH Kapoor TM: Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat Chem Biol 2006, 2(11):618-626. 17028580
71. Gumireddy K Reddy MV Cosenza SC Boominathan R Baker SJ Papathi N Jiang J Holland J Reddy EP: ON0 a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 1910, 7(3):275-286. 15766665
72. Jimeno A Li J Messersmith WA Laheru D Rudek MA Maniar M Hidalgo M Baker SD Donehower RC: Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008, 26(34):5504-5510. 18955447
73. Santamaria A Neef R Eberspacher U Eis K Husemann M Mumberg D Prechtl S Schulze V Siemeister G Wortmann L: Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell 2007, 18(10):4024-4036. 1995727 17671160
74. McInnes C Mazumdar A Mezna M Meades C Midgley C Scaerou F Carpenter L Mackenzie M Taylor P Walkinshaw M: Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol 2006, 2(11):608-617. 17028581
75. Elia AE Cantley LC Yaffe MB: Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science 2003, 299(5610):1228-1231. 12595692
76. Cheng KY Lowe ED Sinclair J Nigg EA Johnson LN: The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. Embo J 2003, 22(21):5757-5768. 275415 14592974
77. Jang YJ Lin CY Ma S Erikson RL: Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc Natl Acad Sci USA 2002, 99(4):1984-1989. 122306 11854496
78. Seong YS Kamijo K Lee JS Fernandez E Kuriyama R Miki T Lee KS: A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J Biol Chem 2002, 277(35):32282-32293. 12034729
79. Reindl W Yuan J Kramer A Strebhardt K Berg T: Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 2008, 15(5):459-466. 18482698
80. Takai N Hamanaka R Yoshimatsu J Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene 2005, 24(2):287-291. 15640844
81. Eckerdt F Yuan J Strebhardt K: Polo-like kinases and oncogenesis. Oncogene 2005, 24(2):267-276. 15640842
82. Simizu S Osada H: Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nat Cell Biol 2000, 2(11):852-854. 11056542
83. Buchner J: Hsp90 & Co. - a holding for folding. Trends Biochem Sci 1999, 24(4):136-141. 10322418
84. Li B Ouyang B Pan H Reissmann PT Slamon DJ Arceci R Lu L Dai W: Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas. The Journal of biological chemistry 1996, 271(32):19402-19408. 8702627
85. Dai W Li Y Ouyang B Pan H Reissmann P Li J Wiest J Stambrook P Gluckman JL Noffsinger A: PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer. Genes, chromosomes & cancer 2000, 27(3):332-336. 10679924
86. Dai W Liu T Wang Q Rao CV Reddy BS: Down-regulation of PLK3 gene expression by types and amount of dietary fat in rat colon tumors. International journal of oncology 2002, 20(1):121-126. 11743651
87. Yang Y Bai J Shen R Brown SA Komissarova E Huang Y Jiang N Alberts GF Costa M Lu L: Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. Cancer Res 2008, 68(11):4077-4085. 18519666
88. Hammond C Jeffers L Carr BI Simon D: Multiple genetic alterations, 4q28, a new suppressor region, and potential gender differences in human hepatocellular carcinoma. Hepatology (Baltimore, Md) 1999, 29(5):1479-1485. 10216132
89. Ko MA Rosario CO Hudson JW Kulkarni S Pollett A Dennis JW Swallow CJ: Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nature genetics 2005, 37(8):883-888. 16025114
90. Brittle AL Ohkura H: Centrosome maturation: Aurora lights the way to the poles. Curr Biol 2005, 15(21):R880-882. 16271861
91. Carmena M Earnshaw WC The cellular geography of aurora kinases. Nature reviews 2003, 4(11):842-854. 14625535
92. Marumoto T Zhang D Saya H: Aurora-A - a guardian of poles. Nat Rev Cancer 2005, 5(1):42-50. 15630414
93. Lu LY Wood JL Ye L Minter-Dykhouse K Saunders TL Yu X Chen J: Aurora A is essential for early embryonic development and tumor suppression. J Biol Chem 2008, 283(46):31785-31790. 18801727
94. Sasai K Parant JM Brandt ME Carter J Adams HP Stass SA Killary AM Katayama H Sen S: Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality. Oncogene 2008, 27(29):4122-4127. 18345035
95. Macurek L Lindqvist A Lim D Lampson MA Klompmaker R Freire R Clouin C Taylor SS Yaffe MB Medema RH: Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008, 455(7209):119-123. 18615013
96. Seki A Coppinger JA Jang CY Yates JR Fang G: Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 2008, 320(5883):1655-1658. 18566290